CLAIMS

What is claimed is:

1. Use of an anti-CGRP antibody comprising the light chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 224; SEQ ID NO: 226; and SEQ ID NO: 228, respectively and heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 204; SEQ ID NO: 206; and RESIDUE GDI (SEE PAGE 2, TABLE A, ITEM NO. 11), respectively, in the manufacture of a medicament for the treatment of cluster headache (such as chronic cluster headache or episodic cluster headache) in a patient with cluster headache symptoms or for prevention of cluster headache in a patient in need of preventative treatment of cluster headache (such as chronic cluster headache or episodic cluster headache),

wherein said medicament comprises 400 mg of said anti-CGRP antibody, and

wherein said anti-CGRP antibody is to be administered intravenously to the patient.

2. The use of claim 1, wherein said patient exhibits at least one cluster headache symptom at the time of administration.

3. The use of claim 1 or 2, wherein the patient experiences at least five attacks according to the blow list A to C:

A. Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15–180 minutes (when untreated)

B. 1 and/or 2 of the following:

(1) at least one of the following symptoms or signs, ipsilateral to the headache:

i. conjunctival injection and/or lacrimation

ii. nasal congestion and/or rhinorrhea

iii. eyelid oedema

iv. forehead and facial sweating

v. miosis and/or ptosis

(2) a sense of restlessness or agitation

C. Occurring with a frequency between one every other day and eight per day.

4. The use of any one of claims 1-3, wherein said patient has had or been diagnosed with cluster headache for at least 3 months, at least 6 months, at least 9 months, for at least a year, for at least 2 years, for at least 3 years, or more than 3 years.

5. The use of any one of claims 1-4, wherein said patient classifies according to the following one or more criteria: is male, is a smoker, is between the age of about 20 to about 50 years, has a family

history of cluster headache, is using a medication such as nitroglycerin, or other drug used to treat heart disease, has been diagnosed with abnormalities in the body's biological clock (hypothalamus), the cluster headache is typically not associated with triggers, such as foods, hormonal changes or stress, or upon the onset of a cluster period alcohol use exacerbates or triggers more headaches or increased head pain.

6. The use of any one of claims 1-5, wherein said patient experiences head pain.

7. The use of any one of claims 1-6, wherein the cluster headache sign or symptom is alleviated immediately after said administration, such as within the first day after administration, within 12 hours after administration, within 6 hours after administration within 5 hours after administration, within 4 hours after administration, within 3 hours after administration, within 2 hours after administration, or within 1 hour of after administration, within 30 minutes after administration, or such as between 1-6 hours after administration.

8. The use of any one of claims 1-7, wherein said patient no longer has a cluster headache after said administration, such as within the first day after administration, within 12 hours after administration, within 6 hours after administration within 5 hours after administration, within 4 hours after administration, within 3 hours after administration, within 2 hours after administration, or within 1 hour of after administration, within 30 minutes after administration, or such as between 1-6 hours after administration.

9. The use of any one of the foregoing claims, wherein said anti-CGRP antibody comprises the light chain polypeptide of SEQ ID NO: 221 and the heavy chain polypeptide of SEQ ID NO: 201 or SEQ ID NO: 566.

10. The use of any one of the foregoing claims, wherein said anti-CGRP antibody comprises the light chain polypeptide encoded by SEQ ID NO: 231 and the heavy chain polypeptide encoded by SEQ ID NO: 211 or SEQ ID NO: 567.

11. The use of any one of the foregoing claims, wherein the cluster headache signs or symptoms decline or are abolished immediately after administration, such as within the first day after administration, within 12 hours after administration, within 6 hours after administration within 5 hours after administration, within 4 hours after administration, within 3 hours after administration, within 2 hours after administration, or within 1 hour of after administration, within 30 minutes after administration, or such as between 1-6 hours after administration.

12. The use of any one of the foregoing claims, wherein said patient is cluster headache free 2 hours post-completion of infusion.

13. The use of any one of claims 1-23, wherein 400 mg of said anti-CGRP antibody is to be administered intravenously every 10-14 weeks, preferably every 11-13 weeks, more preferably every 12 weeks.

14. The use of any one of the foregoing claims, wherein said anti-CGRP antibody is comprised in a formulation comprising or consisting of histidine (L-histidine), sorbitol, polysorbate 80, and water.

15. The use of claim 14, wherein said formulation comprises or consists of, per 1 mL volume, 100 mg anti-CGRP antibody, 3.1 mg L-Histidine, 40.5 mg Sorbitol, and 0.15 mg Polysorbate 80, or having amounts of each constituent within +/- 10% of said values, and having a pH of 5.8 or within +/- 10% of said value.